{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"45.80","upperLimit":"64.36","value":"52.70"},{"groupId":"OG001","lowerLimit":"31.93","upperLimit":"43.76","value":"37.75"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"550"},{"groupId":"OG001","value":"546"}],"units":"Participants"}],"description":"Overall survival is defined as the time from randomization to the date of death from any cause. For subjects that are alive, their survival time will be censored at the date of last contact (\"last known alive date\"). Overall survival will be censored for subjects at the date of randomization if they were randomized but had no follow-up. Survival follow-up will be conducted every 3 months after subject's off-treatment date.","dispersionType":"95% Confidence Interval","groups":[{"description":"Nivolumab 3 mg/kg combined with Ipilimumab 1 mg/kg solutions intravenously every 3 weeks for 4 doses then Nivolumab 3 mg/kg solutions intravenously every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends","id":"OG000","title":"Nivolumab + Ipilimumab"},{"description":"Sunitinib 50 mg capsules by mouth once daily for 4 weeks then 2 weeks off, continuously until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends After completion of final analysis eligible participants may switch from receiving Sunitinib to receiving Nivolumab 3 mg/kg IV combined with Ipilimumab 1 mg/kg IV every 3 weeks for 4 doses then Nivolumab 240mg flat dose IV every 2 weeks","id":"OG001","title":"Sunitinib"}],"paramType":"MEDIAN","populationDescription":"All Randomized","reportingStatus":"POSTED","timeFrame":"From the date of randomization to the date of death (assessed up to approximately 125 months and 6 days)","title":"Overall Survival (OS) in Any Risk Participants With Previously Untreated Metastatic Renal Cell Carcinoma (mRCC)","type":"SECONDARY","unitOfMeasure":"months"}